BioCentury | Jul 10, 2020
Product Development

IQVia’s Dreyer on how real-world data are poised to break new ground

...the world’s largest CROs, Quintiles Transnational Holdings Inc., with one of the largest data companies, IMS Health Holdings Inc....
BioCentury | Sep 21, 2018
Politics, Policy & Law

FDA’s inflection point

...in 1989, and it has been losing them ever since. In 2011, in Sorrell v. IMS Health...
BioCentury | Sep 8, 2017
Company News

Management tracks: Karolinska, Conatus, Theranexus

...plc (NASDAQ:OXFD) named Stefan Linn COO. He was SVP of strategy and commercial operations for IMS Health Holdings Inc....
BioCentury | Aug 19, 2016
Politics & Policy

Study: More scripts filled among ACA-covered patients

...see BioCentury, June 24, 2013) . The new paper's authors evaluated prescription transaction data from IMS Health...
BioCentury | Jul 25, 2016
Strategy

Eurosimilars

...the U.S. Across Europe, price reductions following biosimilar introduction vary widely. For example, according to IMS Health...
...Incheon, South Korea European Medicines Agency (EMA) , London, U.K. Finnish Medicines Agency, Helsinki, Finland IMS Health...
BioCentury | May 9, 2016
Company News

IMS Health, Quintiles deal

...revenues of $5.7 billion, and IMS posted revenues of $2.9 billion for the same period. IMS Health Holdings Inc....
BioCentury | May 4, 2016
Company News

Quintiles, IMS Health merging

...CRO Quintiles Transnational Holdings Inc. (NYSE:Q) and healthcare data and IT company IMS Health Holdings Inc. (NYSE:IMS) are merging...
...an all-stock deal. The parties expect the deal to close next half. The companies said IMS Health...
BioCentury | Apr 15, 2016
Top Story

IMS: Drug spending growth slows in 2015

...on new HCV therapies and price increases -- have leveled off. For the first time, IMS Health...
...and payer negotiating power, and increased competition, particularly in diabetes, slowed price increases. By 2020, IMS Health...
BioCentury | Jan 13, 2016
Company News

Amgen gives Repatha, romosozumab updates

...to Repatha, based on negotiated contracts with payers and PBMs. Amgen also presented data from IMS Health...
BioCentury | Oct 26, 2015
Politics, Policy & Law

Freeing speech

...expenditures in support of candidates. William H. Sorrell, Attorney General of Vermont, et al. v. IMS Health...
Items per page:
1 - 10 of 60
BioCentury | Jul 10, 2020
Product Development

IQVia’s Dreyer on how real-world data are poised to break new ground

...the world’s largest CROs, Quintiles Transnational Holdings Inc., with one of the largest data companies, IMS Health Holdings Inc....
BioCentury | Sep 21, 2018
Politics, Policy & Law

FDA’s inflection point

...in 1989, and it has been losing them ever since. In 2011, in Sorrell v. IMS Health...
BioCentury | Sep 8, 2017
Company News

Management tracks: Karolinska, Conatus, Theranexus

...plc (NASDAQ:OXFD) named Stefan Linn COO. He was SVP of strategy and commercial operations for IMS Health Holdings Inc....
BioCentury | Aug 19, 2016
Politics & Policy

Study: More scripts filled among ACA-covered patients

...see BioCentury, June 24, 2013) . The new paper's authors evaluated prescription transaction data from IMS Health...
BioCentury | Jul 25, 2016
Strategy

Eurosimilars

...the U.S. Across Europe, price reductions following biosimilar introduction vary widely. For example, according to IMS Health...
...Incheon, South Korea European Medicines Agency (EMA) , London, U.K. Finnish Medicines Agency, Helsinki, Finland IMS Health...
BioCentury | May 9, 2016
Company News

IMS Health, Quintiles deal

...revenues of $5.7 billion, and IMS posted revenues of $2.9 billion for the same period. IMS Health Holdings Inc....
BioCentury | May 4, 2016
Company News

Quintiles, IMS Health merging

...CRO Quintiles Transnational Holdings Inc. (NYSE:Q) and healthcare data and IT company IMS Health Holdings Inc. (NYSE:IMS) are merging...
...an all-stock deal. The parties expect the deal to close next half. The companies said IMS Health...
BioCentury | Apr 15, 2016
Top Story

IMS: Drug spending growth slows in 2015

...on new HCV therapies and price increases -- have leveled off. For the first time, IMS Health...
...and payer negotiating power, and increased competition, particularly in diabetes, slowed price increases. By 2020, IMS Health...
BioCentury | Jan 13, 2016
Company News

Amgen gives Repatha, romosozumab updates

...to Repatha, based on negotiated contracts with payers and PBMs. Amgen also presented data from IMS Health...
BioCentury | Oct 26, 2015
Politics, Policy & Law

Freeing speech

...expenditures in support of candidates. William H. Sorrell, Attorney General of Vermont, et al. v. IMS Health...
Items per page:
1 - 10 of 60